MYND Therapeutics Inc.’s Post

Why does the #HeartHealth indication for #semaglutide mark a new era in obesity care? Because it changes the outlook for #AccessToCare. https://lnkd.in/ejRhCvdQ Once firmly shut, "the door is opening" for #Medicare to cover #Wegovy, reports STAT, because of its new indication to prevent heart attacks, strokes, and deaths. https://lnkd.in/e6Smk8Ny

Came across this article by David L. Katz, MD, MPH how he argues that calling obesity a disease contradicts the functioning of our bodies and uses a very clever analogy of drowning. 'We don’t wait for people to drown and devote our focus to resuscitation; we do everything we can to prevent drowning in the first place. We put fences around pools; station lifeguards at the beaches; get our kids to swimming lessons at the first opportunity; and keep a close eye on one another. People still do drown, and so we need medical intervention as well. But that is a last resort, far less good than prevention, and applied far less commonly.' If we are calling obesity a disease, we are shifting our focus to treatment like drugs or bariatric surgeries like in any conventional medicine model and diverting our focus away from health behaviours, socio-economic factors contributing to obesity on an individual and community level. British Society of Lifestyle Medicine

Thanks to BMJ for publishing my letter highlighting the importance of a holistic approach to treating obesity and how drugs like #wegovy and #mounjaro should be used as part of a holistic early intervention strategy to prevent weight related cardiovascular events such as heart attacks and strokes. We are leading the way with our approach at Numan. #obesity #digitalhealth #dosomething #novonordisk #elililly https://lnkd.in/e-ewDt6N

A new diagnostic term, adiposity-based chronic disease (ABCD) is replacing BMI as a way to identify obesity. It's about time, and Carley Rusch, PhD, RDN, LDN, has all the info on how it works and why it's so important in a post in #GenerationsNow: https://bit.ly/4aokVVZ

📢Today is #WorldObesityDay! 📣Let's raise awareness and break stereotypes about obesity💪 🎯Obesity is a disease and requires #publichealth policies and interventions! ✅Today, let's remember that #obesity affects everyone, including those with #FH! FH Europe Foundation European Atherosclerosis Society European Association for the Study of Obesity (EASO)

What steps can we take to combat obesity in type 1 diabetes? Obesity is currently affecting around 650 million people worldwide – as the number is growing, greater action is needed. SOPHIA is working towards finding a shared value with all stakeholders to ensure better treatment of people living with obesity – this includes better obesity management in type 1 diabetes! 💡 A recent SOPHIA publication looked at the interplay between weight gain and escalating insulin dependence. This creates a vicious cycle from which patients struggle to break free. Better education for health care providers is essential to balance treatment risks and benefits. This publication suggests that a multistakeholder initiative is needed – only through shared understanding and joint effort can we combat the emerging threat of obesity in T1D and improve patient outcomes. ➡️ Do you want all the insights? Read the paper here: https://lnkd.in/dkupz_hT Shoutout to the authors of this paper Martin Kueh, Nicholas Chew, Ebaa Al Ozairi and SOPHIA project coordinator Carel W. le Roux. We are excited to follow this important work within #obesityresearch! 💪 _________________ SOPHIA has received funding from the Innovative Medicines Initiatives in 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking support from the European Union’s Horizon 2020 research and innovation program and EFPIA - European Federation of Pharmaceutical Industries and Associations, T1D Exchange, JDRF International, and Obesity Action Coalition through the Innovative Health Initiative (IHI).

⭐The EASO Obesity Taxonomy Words matter and accurate framing and consistent terminology use is vital for ensuring: ✅ accurate diagnosis ✅ effective treatment ✅ consistent research ✅ clear communication ✅ informed policy-making ✅ overall improved patient outcomes. The EASO taxonomy provides a common language and a standardised and consistent framework for defining and classifying obesity. Read more about the six themes👇

🔬 📰 𝗠𝗮𝗷𝗼𝗿 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Eli Lilly’s revolutionary weight loss drug, Tirzepatide, has demonstrated an incredible ⬇️ 94% reduction in the risk of developing Type 2 diabetes, along with up to ⬇️ 22.9% weight loss in adults with prediabetes and obesity. Tirzepatide is reshaping the approach to treating obesity and Type 2 diabetes by targeting both GLP-1 and GIP receptors. This dual-action mechanism offers a new solution for effective weight management and blood sugar control, establishing Tirzepatide as an essential tool for healthcare providers. Not only does Tirzepatide promote significant weight loss, but it also targets the underlying metabolic issues that drive diabetes. As we confront the global obesity crisis, Tirzepatide emerges as a major advancement in treatment, underscoring the crucial need to combine effective medication with lifestyle changes for optimal health outcomes. As we advance into the future of obesity treatment, our friendly, innovative solutions support sustainable health change for medical weight loss programs – prevent and minimize side effects, reduce time burdens, and drive adherence and long-term retention! To learn more about using EW2Health’s solutions in medical weight loss programs to improve patient outcomes and reduce overall treatment costs , visit www.easywaytohealth.com #HealthInnovation #obesity #wellness #health #digitalhealth #startup #predictiveanalytics #personalizedmedicine #research Eli Lilly and Company's Article: https://lnkd.in/gW2UzrpC

What can you do today to tackle obesity and address overall health and wellness? Join Dr. Urvashi Patel and a panel of industry experts as they discuss how to implement an evidence-based obesity treatment strategy. Download our latest report to learn more: https://bit.ly/43krmGc

Obesity Matters is advocating for the public listing of Wegovy® to ensure equitable access to life-changing treatments for obesity and cardiovascular disease. Patients have voiced their strong support for public reimbursement, emphasizing the need for accessible treatments that can reduce the risks of related health issues like diabetes and heart disease. As one patient powerfully shared: “I fight every day for my health. I need more support. Every moment of my life is dedicated to getting better, I can’t give more than that. Stop the bias and give us the safety nets we deserve as humans.” Wegovy offers a dual benefit—helping individuals manage their weight while also addressing cardiovascular risks. By including Wegovy in public health plans, we can help ensure more Canadians have the opportunity to manage their health effectively and live fuller, healthier lives. Together, let’s advocate for better health and more accessible treatments for all Canadians. #HealthEquity #ObesityMatters #Wegovy #BetterHealthcare #PublicHealth #CardiovascularHealth https://ow.ly/4Luu50TLjFz